NEWS

Gwo Xi Stem Cell’s diabetes therapy candidate “GXIPC1®” has successfully secured patents in the United States, China, and Taiwan.

In preparation for future drug approval and global expansion, Gwo Xi Stem Cell is striving to apply PIC/S GMP certification by the end of October in 2025.

Gwo Xi Stem Cell has established partnerships with multiple veterinary clinics, veterinary associations, and distribution partners to build a comprehensive veterinary regenerative medicine network, while continuously expanding its presence in the market.

Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) announced on December 9 that it has obtained the results of its Phase I human clinical trial for type I diabetes in collaboration with Vietnam.

Looking ahead, Dr. Ming-His Chuang explained that Gwo Xi Stem Cell’s primary strategy is to prioritize domestic drug approval, while pursuing out-licensing and strategic partnerships internationally.

Through a solid and well-structured strategy, GWOXI Stem Cell successfully exceeded 100 patent applications in 2023. These patents cover the upstream, midstream, and downstream segments of the cell therapy industry, highlighting the depth and strength of GWOXI’s technological expertise.